AU Patent

AU2022301302A1 — Engineered natural killer (nk) cells and related methods

Assigned to Indapta Therapeutics Inc · Expires 2024-01-25 · 2y expired

What this patent protects

Provided herein are engineered Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), and further comprising a recombinant chimeric antigen receptor (CAR) and compositions thereof. Also provided herein are compositions containing the engineered NK cells and…

USPTO Abstract

Provided herein are engineered Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), and further comprising a recombinant chimeric antigen receptor (CAR) and compositions thereof. Also provided herein are compositions containing the engineered NK cells and methods of making and using the engineered NK cells.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022301302A1
Jurisdiction
AU
Classification
—
Expires
2024-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Indapta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.